Tirapazamine is under clinical development by Teclison and currently in Phase II for Gastroesophageal (GE) Junction Carcinomas. According to GlobalData, Phase II drugs for Gastroesophageal (GE) Junction Carcinomas have a 28% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Tirapazamine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Tirapazamine overview
Tirapazamine is under development for the treatment of metastatic gastrointestinal cancer, neuroendocrine tumor, hepatocellular carcinoma, metastatic colorectal cancer, metastatic gastric cancer, gastroesophageal junction carcinomas and metastatic non-small cell lung cancer. The drug candidate is a benzotriazine di-N-oxide. The therapeutic candidate is administered through intravenous, intrahepatic and intraarterial route. It acts by targeting DNA.
Teclison overview
Teclison is a biotechnology company that focuses on developing therapies for cancer.
For a complete picture of Tirapazamine’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
